2005, Número 1
<< Anterior Siguiente >>
Ann Hepatol 2005; 4 (1)
Combination of Peginterferon α-2b (12 kDa) and Lamivudine in difficult-to-treat chronic hepatitis B- an Indian experience
Amarapurkar DN, Patel ND
Idioma: Ingles.
Referencias bibliográficas: 11
Paginas: 56-59
Archivo PDF: 40.18 Kb.
FRAGMENTO
Sin resumen
REFERENCIAS (EN ESTE ARTÍCULO)
Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: Wilson RA, ed. Viral hepatitis. New York: Marcel Dekker 1997: 315-330.
Cooksley WGE, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. Peginterferon a-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J viral hepatitis 2003; 10: 298-305.
Sung JJY, Chan HLY, Chan FKL, Chim AHL, Wong ML, Leung NWY. Combination of Pegylated interferon and Lamivudine is superior to Lamivudine monotherapy in the treatment of chronic hepatitis B- a randomized trial. J Hepatol 2003; 38 (suppl-2): 33.
Schalm SW. Combination therapy for chronic hepatitis B. J Hepatol 2003; 39: S146-S150.
Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000- summary of a workshop. Gastroenterology 2001; 120: 1828-1853.
Lai CL, Chiewn RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of Lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
Lok AS, McMahon BJ. Chronic hepatitis B- AASLD practice guidelines. Hepatology 2001; 34: 1225-1241.
Janssen HL, Schalm SW, Berk L, Man RA, Heijtink RA. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol 1993; 17(suppl. 3): S47.
Schiff E, Karayalein S, Grimm I, Perrillo R, Dienstag J, Husa P, et al and the International Lamivudine Investigator Group. A placebo controlled study of Lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy (abstract). Hepatology 1998; 28: 388A.
van Zonneveld M, van Nunen AB, Schalm SW, Janssen HLA. Chronic HBV treatment with one year of Pegylated- interferon alpha-2B (PEG-IFN) has a comparable safety profile to short-term conventional interferon alpha-2B. J Hepatol 2003; 38 (suppl-2): 179.